Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
50% of the business is held by the top 8 shareholders Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock A look at the shareholders of Trevi Therapeutics, Inc. ( NASDAQ:TRVI ) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 64% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). And as as result, institutional investors reaped the most rewards after the company's stock price gained 57% last week. The one-year return on investment is currently 101% and last week's gain would have been more than welcomed. Let's delve deeper into each type of owner of Trevi Therapeutics, beginning with the chart below. See our latest analysis for Trevi Therapeutics NasdaqGM:TRVI Ownership Breakdown March 16th 2025 What Does The Institutional Ownership Tell Us About Trevi Therapeutics? Institution
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial OfficerPR Newswire
- Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]Seeking Alpha
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 12/5/25 - Form 8-K
- 12/3/25 - Form 4
- 11/14/25 - Form SCHEDULE
- TRVI's page on the SEC website